Shandong Jincheng Pharmaceutical Group Past Earnings Performance
Past criteria checks 5/6
Shandong Jincheng Pharmaceutical Group has been growing earnings at an average annual rate of 19.5%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 6% per year. Shandong Jincheng Pharmaceutical Group's return on equity is 5.5%, and it has net margins of 5.5%.
Key information
19.5%
Earnings growth rate
19.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 6.0% |
| Return on equity | 5.5% |
| Net Margin | 5.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shandong Jincheng Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,485 | 193 | 959 | 185 |
| 30 Jun 24 | 3,592 | 204 | 990 | 190 |
| 31 Mar 24 | 3,640 | 208 | 1,050 | 194 |
| 31 Dec 23 | 3,538 | 175 | 1,038 | 185 |
| 30 Sep 23 | 3,483 | 147 | 983 | 187 |
| 30 Jun 23 | 3,359 | 156 | 1,038 | 173 |
| 31 Mar 23 | 3,382 | 211 | 1,025 | 156 |
| 01 Jan 23 | 3,506 | 273 | 996 | 171 |
| 30 Sep 22 | 3,634 | 246 | 1,073 | 172 |
| 30 Jun 22 | 3,695 | 234 | 1,110 | 179 |
| 31 Mar 22 | 3,483 | 170 | 1,143 | 181 |
| 01 Jan 22 | 3,138 | 108 | 1,164 | 178 |
| 30 Sep 21 | 3,121 | -576 | 1,234 | 203 |
| 30 Jun 21 | 2,984 | -565 | 1,220 | 199 |
| 31 Mar 21 | 2,920 | -539 | 1,178 | 209 |
| 31 Dec 20 | 2,962 | -489 | 1,132 | 192 |
| 30 Sep 20 | 2,767 | -24 | 1,055 | 180 |
| 30 Jun 20 | 2,786 | 47 | 935 | 212 |
| 31 Mar 20 | 2,811 | 206 | 901 | 230 |
| 31 Dec 19 | 2,795 | 203 | 874 | 264 |
| 30 Sep 19 | 2,809 | 464 | 777 | 262 |
| 30 Jun 19 | 2,780 | 437 | 739 | 251 |
| 31 Mar 19 | 2,815 | 290 | 725 | 230 |
| 31 Dec 18 | 3,008 | 264 | 744 | 218 |
| 30 Sep 18 | 3,082 | 345 | 739 | 190 |
| 30 Jun 18 | 3,087 | 313 | 631 | 225 |
| 31 Mar 18 | 3,043 | 304 | 573 | 185 |
| 31 Dec 17 | 2,788 | 286 | 468 | 139 |
| 30 Sep 17 | 2,483 | 238 | 345 | 90 |
| 30 Jun 17 | 2,115 | 210 | 337 | 0 |
| 31 Mar 17 | 1,739 | 173 | 267 | 0 |
| 31 Dec 16 | 1,420 | 159 | 231 | 0 |
| 30 Sep 16 | 1,133 | 142 | 219 | 0 |
| 30 Jun 16 | 1,104 | 159 | 213 | 0 |
| 31 Mar 16 | 1,156 | 174 | 214 | 0 |
| 31 Dec 15 | 1,179 | 171 | 216 | 0 |
| 30 Sep 15 | 1,146 | 160 | 208 | 0 |
| 30 Jun 15 | 1,142 | 142 | 213 | 0 |
| 31 Mar 15 | 1,091 | 127 | 210 | 0 |
| 31 Dec 14 | 1,051 | 109 | 214 | 0 |
| 30 Sep 14 | 1,023 | 100 | 207 | 0 |
| 30 Jun 14 | 974 | 90 | 190 | 0 |
| 31 Mar 14 | 935 | 71 | 181 | 0 |
| 31 Dec 13 | 909 | 65 | 166 | 0 |
Quality Earnings: 300233 has high quality earnings.
Growing Profit Margin: 300233's current net profit margins (5.5%) are higher than last year (4.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300233's earnings have grown by 19.5% per year over the past 5 years.
Accelerating Growth: 300233's earnings growth over the past year (31.1%) exceeds its 5-year average (19.5% per year).
Earnings vs Industry: 300233 earnings growth over the past year (31.1%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 300233's Return on Equity (5.5%) is considered low.